ECSP034551A - Secretagogos de hormona del crecimiento - Google Patents

Secretagogos de hormona del crecimiento

Info

Publication number
ECSP034551A
ECSP034551A EC2003004551A ECSP034551A ECSP034551A EC SP034551 A ECSP034551 A EC SP034551A EC 2003004551 A EC2003004551 A EC 2003004551A EC SP034551 A ECSP034551 A EC SP034551A EC SP034551 A ECSP034551 A EC SP034551A
Authority
EC
Ecuador
Prior art keywords
alkyl
aryl
hydrogen
group
optionally substituted
Prior art date
Application number
EC2003004551A
Other languages
English (en)
Inventor
Jeffrey Alan Dodge
Brian Stephen Muehl
Louis Nickolaus Jungheim
Britta Evers
Gerd Ruehter
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP034551A publication Critical patent/ECSP034551A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un compuesto de fórmula I: en la que: R1 es NhR10 O alquil C1-C6-NHR10; (gráfico), R10 se selecciona entre el grupo compuesto por hidrógeno, alquilo C1-C6, alquil C1-C6 (OH), alquilidenil C1-C6 (OH) RII, y un grupo protector de amino: RII se selecciona entre el grupo compuesto por alquilo C1-C6, alquenilo C2-C6, alquil C1-C6(0) alquilo C1-C6, C(0) 0-alquilo C1-C6, arilo y alquil C1-C6-arilo; R2 se selecciona entre hidrógeno, alquilo C1-C6, arilo y alquil C1-C6 arilo; R3 se selecciona entre el grupo compuesto por arilo opcionalmente sustituido, alquil C1-C6-arilo, alquil C1-C6(0)-alquil C1-C6 arilo, cicloalquilo C3-C8, (alquil C1-C6) cicloalilo C3-C8, indolilo, indolinilo, (alquil C1-C6) indolilo; R4 es hidrógeno, alquilo C1, C6, arilo y alquil C1-C6-arilo; W es -CH2C2C6H4-o-(CH2) m, donde m es un número seleccionado de 1 a 4: R6 y R7 se seleccionan independientemente entre el grupo compuesto por hidrógeno, alquilo C2-C6, alquenilo C1-C6, o R6 y R7 junto con el átomo del carbono al que están unidos pueden formar un anillo carbocíclico de hasta 8 átomos que opcionalmente está parcialmente insaturado; R8 se selecciona entre el grupo compuesto por hidrógeno, alquilo C1-C6, alquilo C1-C6, arilo y alquil C1-C6, alquenilo C1-C6 arilo; R9se selecciona entre el grupo compuesto por hidrógeno, alquilo C1-C6 alquenilo C2-C6, alquinilo C2-C6, cicloalquilo C3-C8, cicloalquenilo C3-C8, ciano, arilo opcionalmente sustituido, -0-arilo opcionalmente sustituido, -N- arilo opcionalmente sustituido, -S- arilo opcionalmente sustituido-aril-arilo (K1) (K2), -O-aril-arilo (K1) (K2). -N-aril-aril(k1) (K2), -O-alquilo C1-C6, y alquil C1-C6 arilo, donde K1 es halo o - CF3 y K2 es hidrógeno, halo 0 -CF3; y Q es S-(0) 2-o-C(0)-; o una sal o solvato farmaceúticamente aceptable del mismo.
EC2003004551A 2000-10-13 2003-04-10 Secretagogos de hormona del crecimiento ECSP034551A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24045600P 2000-10-13 2000-10-13

Publications (1)

Publication Number Publication Date
ECSP034551A true ECSP034551A (es) 2003-05-26

Family

ID=22906598

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004551A ECSP034551A (es) 2000-10-13 2003-04-10 Secretagogos de hormona del crecimiento

Country Status (26)

Country Link
EP (1) EP1326851B1 (es)
JP (1) JP2004511552A (es)
KR (1) KR20030042014A (es)
CN (1) CN1469871A (es)
AT (1) ATE270280T1 (es)
AU (2) AU2002211219B2 (es)
BR (1) BR0114630A (es)
CA (1) CA2419388A1 (es)
CZ (1) CZ20031029A3 (es)
DE (1) DE60104141T2 (es)
DZ (1) DZ3482A1 (es)
EA (1) EA006102B1 (es)
EC (1) ECSP034551A (es)
ES (1) ES2223926T3 (es)
HR (1) HRP20030288B1 (es)
HU (1) HUP0301351A3 (es)
IL (1) IL154809A0 (es)
MX (1) MXPA03003217A (es)
NO (1) NO20031687L (es)
NZ (1) NZ524232A (es)
PL (1) PL361675A1 (es)
PT (1) PT1326851E (es)
SK (1) SK4182003A3 (es)
TR (1) TR200402046T4 (es)
WO (1) WO2002032888A1 (es)
ZA (1) ZA200301720B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1497316B1 (en) * 2002-04-09 2006-07-05 Eli Lilly And Company Growth hormone secretagogues
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2005028438A1 (ja) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
NZ562766A (en) 2005-05-30 2011-03-31 Banyu Pharma Co Ltd Piperidine derivatives as histamine-H3 receptor antagonists
EP1916239A4 (en) 2005-08-10 2009-10-21 Banyu Pharma Co Ltd PYRIDOLVERBINDUNG
AU2006282260A1 (en) 2005-08-24 2007-03-01 Msd K.K. Phenylpyridone derivative
US20090264426A1 (en) 2005-09-07 2009-10-22 Shunji Sakuraba Bicyclic aromatic substituted pyridone derivative
US8293900B2 (en) 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
US20080255084A1 (en) 2005-10-21 2008-10-16 Randy Lee Webb Combination of Organic Compounds
EP1944301A4 (en) 2005-10-27 2012-01-04 Msd Kk NEW BENZOXATHIIN DERIVATIVES
CA2629018C (en) 2005-11-10 2013-12-31 Banyu Pharmaceutical Co., Ltd. Aza-substituted spiro derivative
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2008038692A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2264026A4 (en) 2008-03-06 2012-03-28 Msd Kk ALKYLAMINOPYRIDINDERIVATE
JPWO2009119726A1 (ja) 2008-03-28 2011-07-28 Msd株式会社 メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20110071129A1 (en) 2008-06-19 2011-03-24 Makoto Ando Spirodiamine-diaryl ketoxime derivative
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010013595A1 (ja) 2008-07-30 2010-02-04 萬有製薬株式会社 5員-5員又は5員-6員縮環シクロアルキルアミン誘導体
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
MX2011004551A (es) 2008-10-30 2011-05-25 Merck Sharp & Dohme Antagonistas del receptor de orexina de isonicotinamida.
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8314250B2 (en) * 2009-11-24 2012-11-20 Hoffmann-La Roche Inc. Sultam derivatives
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
BR112015019836A2 (pt) 2013-02-22 2017-07-18 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
MX389591B (es) 2014-08-29 2025-03-20 Tes Pharma S R L INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA
MX2019004321A (es) 2016-10-14 2019-06-12 Tes Pharma S R L Inhibidores de la acido alfa-amino-beta-carboximuconico semialdehido descarboxilasa.
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
CN118496217A (zh) 2018-11-20 2024-08-16 Tes制药有限责任公司 α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂
US12331018B2 (en) 2019-02-13 2025-06-17 Merck Sharp & Dohme Llc Pyrrolidine orexin receptor agonists
EP3924058B1 (en) 2019-02-13 2026-01-07 Merck Sharp & Dohme LLC 5-alkyl pyrrolidine orexin receptor agonists
US12312332B2 (en) 2019-08-08 2025-05-27 Merck Sharp & Dohme Llc Heteroaryl pyrrolidine and piperidine orexin receptor agonists
US20230365533A1 (en) 2020-08-18 2023-11-16 Merck Sharp & Dohme Llc Bicycloheptane pyrrolidine orexin receptor agonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018815A1 (en) * 1996-10-25 1998-05-07 Merck & Co., Inc. Convergent process for the preparation of a growth hormone secretagogue
UA53716C2 (uk) * 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)

Also Published As

Publication number Publication date
BR0114630A (pt) 2003-07-01
CN1469871A (zh) 2004-01-21
DE60104141D1 (de) 2004-08-05
HRP20030288B1 (en) 2005-02-28
HUP0301351A3 (en) 2007-05-29
EP1326851B1 (en) 2004-06-30
EP1326851A1 (en) 2003-07-16
HUP0301351A2 (hu) 2003-11-28
AU2002211219B2 (en) 2006-09-14
KR20030042014A (ko) 2003-05-27
NO20031687L (no) 2003-05-08
PL361675A1 (en) 2004-10-04
JP2004511552A (ja) 2004-04-15
NO20031687D0 (no) 2003-04-11
CA2419388A1 (en) 2002-04-25
HRP20030288A2 (en) 2004-02-29
EA200300462A1 (ru) 2003-08-28
CZ20031029A3 (cs) 2003-09-17
MXPA03003217A (es) 2003-06-06
EA006102B1 (ru) 2005-08-25
ZA200301720B (en) 2004-06-21
WO2002032888A1 (en) 2002-04-25
PT1326851E (pt) 2004-11-30
ES2223926T3 (es) 2005-03-01
HK1058194A1 (en) 2004-05-07
DZ3482A1 (fr) 2002-04-25
SK4182003A3 (en) 2004-01-08
TR200402046T4 (tr) 2004-10-21
ATE270280T1 (de) 2004-07-15
IL154809A0 (en) 2003-10-31
AU1121902A (en) 2002-04-29
NZ524232A (en) 2005-01-28
DE60104141T2 (de) 2005-06-30

Similar Documents

Publication Publication Date Title
ECSP034551A (es) Secretagogos de hormona del crecimiento
CO4790091A1 (es) Derivados sustituidos de acido 3-sulfonil-propionico
CO4950563A1 (es) Nuevos compuestos
UY28878A1 (es) Compuestos de aril-o heteroarilamida ortosustituidos y composiciones
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
AR008377A1 (es) Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto
SG165154A1 (en) Ester compound and medical use thereof
PE49696A1 (es) Compuesto carbociclico
DOP2005000071A (es) "compuestos de metil-aril o heteroaril-amida sustituida"
DE60315615D1 (de) Tricyclische verbindungen auf thiophengrundlage und pharmazeutische zusammensetzungen, die diese enthalten
PE20021004A1 (es) Derivados de piperidina como inhibidores de la ccr5
AR064253A1 (es) Compuestos de biciclocarboxiamida sustituidos composiciones farmaceuticas y una combinacion que los incluye y su uso en fabaricacion de un medicamento para el tratamiento de enfermedades mediadas por la actividad del receptor vr1
ES2095942T3 (es) Derivados de bencenoacetamida inhibidores del vih.
TW200612920A (en) Novel imidazolidine derivatives
AR033300A1 (es) Compuestos de cefem
ES2143644T3 (es) Procedimiento para elaborar compuestos antimicrobianos.
TW200509942A (en) Substituted 1,4-diazepines and uses thereof
HU9300176D0 (en) Method for producing unsaturated 17beta-substituted 3-carboxy steroides
AR025296A1 (es) MÉTODO PARA INHIBIR LA POLIMERIZACIoN PREMATURA DE MONoMEROS VINIL AROMÁTICOS Y COMPOSICIoN DE MONoMEROS VINIL AROMÁTICOS Y DEL INHIBIDOR.
CO5700768A2 (es) Derivados de benzoxazina y sus usos
WO2004080408A3 (en) Method of treating cancer with azaspirane compositions
UY23452A1 (es) Procedimiento para la preparacion de derivados de ciclohexano y tetrahidropirano
DK0988312T3 (da) 17beta-allyloxy(thio)alkyl-androstanderivater til modulering af meiose
CO4650039A1 (es) Benzotiofenos amorfos, procedimientos de preparacion y procedimientos de uso
ATE356816T1 (de) Trizyklische keto amid derivative als farnesyl protein transferase inhibitoren